A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects

耐受性 药代动力学 安慰剂 医学 加药 内科学 不利影响 替代医学 病理
作者
James Ermer,Patrick Martin,Mary Corcoran,Yumiko Matsuo
出处
期刊:Neuropsychopharmacology reports [Wiley]
卷期号:40 (1): 16-29 被引量:3
标识
DOI:10.1002/npr2.12082
摘要

Abstract Aim To assess safety, tolerability, and pharmacokinetics of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adults. Methods A phase 1, double‐blind, randomized, placebo‐controlled, single‐ and multiple‐dose study in Japanese and Caucasian subjects. Subjects received lisdexamfetamine 20 mg or placebo on Day 1, then lisdexamfetamine 20 mg/d (Days 4‐8), 50 mg/d (Days 9‐13), 70 mg/d (Days 14‐18), or matching placebo. Pharmacokinetic parameters for lisdexamfetamine and d ‐ amphetamine were estimated by noncompartmental analysis. Results Fifteen Japanese and 19 Caucasian subjects were enrolled and randomized. The lisdexamfetamine and d ‐ amphetamine plasma concentration‐time curves were similar for both ethnic groups following single and multiple doses. Mean area under the concentration‐time curves for d ‐ amphetamine were higher (by 11%‐15%) in Japanese than Caucasian subjects following multiple dosing of lisdexamfetamine. Mean bodyweight was 17% lower in Japanese than Caucasian subjects. Weight‐corrected means for oral clearance were similar in both ethnic groups, with no unexpected accumulation of d ‐ amphetamine. Lisdexamfetamine was generally well tolerated by both ethnic groups, with no serious adverse events reported. The 10/12 Japanese and 11/16 Caucasian subjects who received lisdexamfetamine completed the study; two Japanese and three Caucasian subjects discontinued due to adverse events. Most adverse events were of mild severity. Conclusion Pharmacokinetics were generally similar for Japanese and Caucasian subjects; the minor differences observed were likely due to bodyweight differences in the two ethnic groups. Lisdexamfetamine was generally well tolerated. Adverse events were consistent with the established safety profile of lisdexamfetamine and were similar in both ethnic groups.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
woods完成签到,获得积分10
14秒前
西山菩提完成签到,获得积分10
15秒前
16秒前
MRJJJJ完成签到,获得积分10
17秒前
甜蜜的白桃完成签到 ,获得积分10
17秒前
Waymaker完成签到 ,获得积分10
22秒前
_firework_完成签到,获得积分20
23秒前
雨后完成签到 ,获得积分10
26秒前
鹏鱼燕完成签到,获得积分10
30秒前
herpes完成签到 ,获得积分0
31秒前
成就大白菜真实的钥匙完成签到 ,获得积分10
34秒前
cdercder应助科研通管家采纳,获得10
37秒前
cdercder应助科研通管家采纳,获得10
37秒前
有魅力天抒完成签到 ,获得积分10
46秒前
51秒前
优美尔珍完成签到,获得积分10
53秒前
大熊完成签到 ,获得积分10
57秒前
舒心如凡完成签到,获得积分10
1分钟前
健康的大门完成签到,获得积分10
1分钟前
开心夏旋完成签到 ,获得积分10
1分钟前
iorpi完成签到,获得积分10
1分钟前
又又完成签到,获得积分10
1分钟前
吉吉完成签到 ,获得积分10
1分钟前
笨笨忘幽完成签到,获得积分10
1分钟前
科研通AI2S应助jjdeng采纳,获得10
1分钟前
故意的书本完成签到 ,获得积分10
1分钟前
ocean完成签到,获得积分10
1分钟前
文献搬运工完成签到 ,获得积分10
1分钟前
CLTTT完成签到,获得积分10
1分钟前
1分钟前
xiaofan完成签到,获得积分10
1分钟前
居里姐姐完成签到 ,获得积分10
1分钟前
理想完成签到,获得积分10
2分钟前
jjdeng完成签到,获得积分10
2分钟前
单小芫完成签到 ,获得积分10
2分钟前
monk完成签到 ,获得积分10
2分钟前
温暖完成签到 ,获得积分10
2分钟前
资白玉完成签到 ,获得积分10
2分钟前
个性仙人掌完成签到 ,获得积分10
2分钟前
龙王爱吃糖完成签到 ,获得积分10
2分钟前
高分求助中
Applied Survey Data Analysis (第三版, 2025) 800
Assessing and Diagnosing Young Children with Neurodevelopmental Disorders (2nd Edition) 700
Images that translate 500
引进保护装置的分析评价八七年国外进口线路等保护运行情况介绍 500
Algorithmic Mathematics in Machine Learning 500
Handbook of Innovations in Political Psychology 400
Mapping the Stars: Celebrity, Metonymy, and the Networked Politics of Identity 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3840870
求助须知:如何正确求助?哪些是违规求助? 3382770
关于积分的说明 10526510
捐赠科研通 3102624
什么是DOI,文献DOI怎么找? 1708930
邀请新用户注册赠送积分活动 822781
科研通“疑难数据库(出版商)”最低求助积分说明 773632